An exposé of Boston area drug developer Integral BioSystems LLC is now available in the ARVO News Spring 2017 Edition posted on the ARVO website.

BEDFORD, MASSACHUSETTS, USA, April 17, 2017 /EINPresswire.com/ -- Bedford, MA – April 14, 2017 – Integral BioSystems LLC, a Boston area company specializing in ophthalmological pharmaceutical formulation development offering services as a CRO performing contract drug development, as well as partnering opportunities involving its proprietary, patent-protected drug delivery platforms, is in the spotlight as an important player in the contract research and development industry in an article on the website of the Association for Research in Vision and Ophthalmology (ARVO).

The article is based on an interview of Integral’s Founder, Dr. Shikha P. Barman, who is also the company’s President and CEO, drawing on Dr. Barman’s 25 years of experience in all phases of cell and tissue targeted, sustained release pharmaceutical formulation development. Under Dr. Barman’s auspices, Integral BioSystems will present 2 technical posters at the ARVO 2017 Annual Meeting and Symposium.

About the Symposium
The ARVO 2017 Annual Meeting of the Association for Research in Vision and Ophthalmology will cover subjects like Medicine, Eyesight, Vision, Ophthalmology, and Eye Health. This gathering of scientists, medical personnel, and representatives from related businesses combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services. It is anticipated that more than 11,000 people will participate in this Meeting.

About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.

The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.

Dave Karasic
Integral BioSystems, LLC
781-275-8059
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.